Compounds > lenalidomide
Page last updated: 2024-09-05

lenalidomide and Pyoderma Gangrenosum

lenalidomide has been researched along with Pyoderma Gangrenosum in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Bessis, D; Cezar, R; Corbeau, P; Poujade, L; Samaran, Q; Sarrabay, G; Tran, TA1
Cahn, JY; Courby, S; Deteix, C; Larabi, A; Meunier, M; Schacherer, M1
Alexandrescu, DT; Bockorny, B; Dasanu, CA1

Other Studies

3 other study(ies) available for lenalidomide and Pyoderma Gangrenosum

ArticleYear
Lenalidomide for treatment of refractory aphthosis and neutrophilic pustulosis in familial pyrin-associated autoinflammation with neutrophilic dermatosis.
    Rheumatology (Oxford, England), 2023, 12-01, Volume: 62, Issue:12

    Topics: Dermatitis; Humans; Lenalidomide; Neutrophils; Pyoderma Gangrenosum; Pyrin; Stomatitis, Aphthous

2023
Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma.
    Annals of hematology, 2020, Volume: 99, Issue:2

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Substitution; Febrile Neutropenia; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Piperacillin, Tazobactam Drug Combination; Pyoderma Gangrenosum; Thalidomide

2020
Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2015, Volume: 21, Issue:6

    Topics: Aged, 80 and over; Angiogenesis Inhibitors; Blood Cell Count; Fatal Outcome; Humans; Knee; Lenalidomide; Male; Multiple Myeloma; Pyoderma Gangrenosum; Skin; Thalidomide

2015